Immix Biopharma, Inc.
$10.09
▲
3.71%
2026-04-21 07:29:01
www.immixbio.com
NCM: IMMX
Explore Immix Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$548.68 M
Current Price
$10.09
52W High / Low
$11.61 / $1.57
Stock P/E
—
Book Value
$1.77
Dividend Yield
—
ROCE
-31.62%
ROE
-55%
Face Value
—
EPS
$-0.89
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.21
Debt / Equity
1.14
Current Ratio
10.01
Quick Ratio
10.01
Forward P/E
-12.73
Price / Sales
—
Enterprise Value
$391.12 M
EV / EBITDA
-13.16
EV / Revenue
—
Rating
Strong Buy
Target Price
$17.56
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
| 2. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
| 3. | Decoy Therapeutics Inc. | $5.89 | — | $3.09 M | — | -379.33% | -3.38% | $415.8 / $5.4 | $11.07 |
| 4. | GH Research PLC | $21.5 | — | $1.33 B | — | -21.68% | -21.04% | $24.66 / $8.66 | $4.51 |
| 5. | Beam Therapeutics Inc. | $31.19 | — | $3.2 B | — | -27.72% | -8.11% | $36.44 / $15.35 | $12.48 |
| 6. | CalciMedica, Inc. | $0.66 | — | $9.49 M | — | -235.71% | -7.61% | $7.2 / $0.46 | $-0.43 |
| 7. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -10.89 M | -7.66 M | -6.72 M | -4.68 M | -4.99 M | — |
| Net Profit | -10.69 M | -7.59 M | -6.62 M | -4.54 M | -4.81 M | — |
| EPS in Rs | -0.2 | -0.14 | -0.12 | -0.09 | -0.09 | -0.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -29.96 M | -22.67 M | -16.14 M | -8.22 M |
| Net Profit | -29.44 M | -21.61 M | -15.43 M | -8.23 M |
| EPS in Rs | -0.56 | -0.41 | -0.29 | -0.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 104.84 M | 22.95 M | 19.93 M | 14.91 M |
| Total Liabilities | 11.04 M | 9.7 M | 3.72 M | 1.75 M |
| Equity | 93.8 M | 13.25 M | 16.41 M | 13.16 M |
| Current Assets | 101.24 M | 20.2 M | 19.79 M | 14.9 M |
| Current Liabilities | 10.11 M | 8.69 M | 3.72 M | 1.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.93 M | -14.6 M | -11.37 M | -7.41 M |
| Investing CF | -7.21 M | -1.18 M | -0.05 M | 0 M |
| Financing CF | 107.39 M | 15.95 M | 15.46 M | 3.23 M |
| Free CF | -24.66 M | -15.77 M | -11.42 M | -7.41 M |
| Capex | -0.73 M | -1.18 M | -0.05 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -40.11% | -87.44% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.